Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_3
2
67%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 32 (66.7%)

Trials by Status

recruiting133%
completed133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

Recombinant vWF Concentrate and ECMO

NCT06118372
completedphase_3

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

NCT04344860
terminatedphase_3

Minimize Menorrhagia in Women With Von Willebrand Disease

NCT02606045

Clinical Trials (3)

Showing 3 of 3 trials
NCT06118372Phase 1

Recombinant vWF Concentrate and ECMO

Recruiting
NCT04344860Phase 3

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

Completed
NCT02606045Phase 3

Minimize Menorrhagia in Women With Von Willebrand Disease

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3